Avelumab displayed antitumor activity with manageable toxicity in patients with previously treated mCRC harboring dMMR/MSI-H. Further clinical studies with larger sample sizes are necessary to evaluate the activity of ICIs and its association with sites in POLE-mutated CRC. This evidence concerns the gene POLE and colorectal carcinoma.